Ahzantive: Uses, Dosage & Side Effects

What Is Ahzantive and What Is It Used For?

Ahzantive contains the active substance adalimumab, a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. As a biosimilar to the reference product Humira (adalimumab), Ahzantive has been demonstrated through comprehensive analytical, preclinical, and clinical studies to be highly similar to the reference product with no clinically meaningful differences in safety, purity, or potency. Biosimilars are biological medicines that are highly similar to an already-approved biological medicine (the reference product) and meet the rigorous standards set by regulatory authorities such as the U.S. Food and Drug Administration (FDA).

Adalimumab works by specifically binding to tumor necrosis factor alpha (TNF-alpha), one of the most important pro-inflammatory cytokines in the human immune system. TNF-alpha is a naturally occurring protein that plays a central role in regulating the immune response and inflammation. Under normal circumstances, TNF-alpha helps the body fight infections and heal injuries. However, in autoimmune diseases, the immune system produces excessive amounts of TNF-alpha, which leads to chronic inflammation that attacks the body’s own tissues. This abnormal TNF-alpha activity drives the tissue damage, pain, swelling, and progressive destruction seen in conditions like rheumatoid arthritis, inflammatory bowel disease, and psoriasis.

By binding to both soluble and membrane-bound forms of TNF-alpha with high affinity and specificity, adalimumab neutralizes its biological activity. Specifically, adalimumab prevents TNF-alpha from interacting with its cell surface receptors (p55/TNFR1 and p75/TNFR2), thereby blocking the downstream inflammatory signaling cascade. This includes reducing the levels of other inflammatory mediators such as interleukin-6 (IL-6), matrix metalloproteinases (which cause tissue destruction), and adhesion molecules (which recruit inflammatory cells to sites of damage). In patients with rheumatoid arthritis, adalimumab has been shown to reduce levels of C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), and other markers of systemic inflammation.

Ahzantive is indicated for the treatment of multiple immune-mediated inflammatory conditions in adults and, for some indications, in pediatric patients. The approved indications include:

• Rheumatoid Arthritis (RA): For reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural joint damage, and improving physical function in adult patients with moderately to severely active RA. Adalimumab can be used alone or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs (DMARDs).
• Psoriatic Arthritis (PsA): For reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active PsA. It can be used alone or in combination with non-biologic DMARDs.
• Ankylosing Spondylitis (AS): For reducing signs and symptoms in adult patients with active ankylosing spondylitis.
• Crohn’s Disease (CD): For reducing signs and symptoms and inducing and maintaining clinical remission in adult patients with moderately to severely active Crohn’s disease who have had an inadequate response to conventional therapy.
• Ulcerative Colitis (UC): For inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis who have had an inadequate response to immunosuppressants such as corticosteroids, azathioprine, or 6-mercaptopurine.
• Plaque Psoriasis (Ps): For the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy and when other systemic therapies are medically less appropriate.
• Hidradenitis Suppurativa (HS): For the treatment of moderate to severe hidradenitis suppurativa in adult patients.
• Non-Infectious Uveitis: For the treatment of non-infectious intermediate, posterior, and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients requiring corticosteroid-sparing therapy, or in patients in whom corticosteroid treatment is inappropriate.

The clinical efficacy and safety of adalimumab have been extensively studied in numerous large-scale randomized controlled trials involving thousands of patients across all approved indications. The totality of evidence from these trials demonstrates that adalimumab provides significant clinical benefit in reducing disease activity, preventing structural damage (in joint diseases), improving quality of life, and reducing the burden of disease. The biosimilarity of Ahzantive to the reference product has been established through a comprehensive stepwise approach including analytical characterization, functional assays, pharmacokinetic/pharmacodynamic studies, and a clinical confirmatory study demonstrating equivalent efficacy and comparable safety and immunogenicity.

What Should You Know Before Taking Ahzantive?

Contraindications

Ahzantive is contraindicated in patients with known hypersensitivity to adalimumab or any of the excipients in the formulation. Excipients include sodium chloride, dibasic sodium phosphate dihydrate, monobasic sodium phosphate dihydrate, sodium citrate, citric acid monohydrate, mannitol, polysorbate 80, and water for injection. If you have ever had a severe allergic reaction to adalimumab or any product containing these ingredients, you must not use Ahzantive.

Additionally, adalimumab should not be used in combination with anakinra (an interleukin-1 receptor antagonist) due to an increased risk of serious infections without additional clinical benefit. The combination of adalimumab with abatacept (a selective T-cell co-stimulation modulator) is also not recommended due to similar concerns about increased infection risk. Patients with active tuberculosis or other active serious infections (including sepsis, opportunistic infections, and active hepatitis B) should not initiate treatment with Ahzantive until the infection has been adequately treated.

Warnings and Precautions

Before starting treatment with Ahzantive, your doctor should conduct a thorough evaluation including:

• Tuberculosis screening: All patients must be evaluated for active and latent tuberculosis before initiating therapy. This typically involves a tuberculin skin test (TST) or interferon-gamma release assay (IGRA), along with a chest radiograph. Patients with latent TB must begin treatment for latent TB before starting Ahzantive. Patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed should also receive TB treatment before starting adalimumab. Monitoring for signs and symptoms of active TB should continue during and after treatment, even in patients with an initially negative TB test.
• Hepatitis B screening: Reactivation of hepatitis B virus (HBV) has occurred in chronic carriers of HBV receiving TNF-alpha inhibitors. Some cases have been fatal. All patients should be tested for HBV infection before initiating TNF-alpha inhibitor therapy. Carriers of HBV should be closely monitored for clinical and laboratory signs of active HBV infection throughout treatment and for several months after discontinuation. If HBV reactivation occurs, Ahzantive should be stopped and effective antiviral therapy along with appropriate supportive treatment should be initiated.
• Malignancies: Lymphoma and other malignancies, some fatal, have been reported in children and adolescents treated with TNF-alpha inhibitors. Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare and aggressive type of lymphoma, have been reported in patients treated with TNF-alpha inhibitors, particularly in young patients with Crohn’s disease or ulcerative colitis receiving concomitant azathioprine or 6-mercaptopurine. The potential role of TNF-alpha inhibitor therapy in the development of malignancies is not fully understood. Patients with a current or past history of malignancy should be evaluated carefully before starting treatment.
• Heart failure: TNF-alpha inhibitors including adalimumab have been associated with worsening or new onset of congestive heart failure (CHF). Patients with moderate to severe heart failure (NYHA Class III/IV) should not be treated with Ahzantive. Patients with mild heart failure (NYHA Class I/II) should be monitored carefully, and treatment should be discontinued if new or worsening heart failure symptoms develop.
• Demyelinating disorders: Use of TNF-alpha inhibitors has been associated with rare cases of new-onset or exacerbation of central nervous system demyelinating diseases, including multiple sclerosis and optic neuritis, as well as peripheral demyelinating diseases including Guillain-Barré syndrome. Exercise caution when considering adalimumab in patients with pre-existing or recent-onset demyelinating disorders.

Pregnancy and Breastfeeding

Ahzantive should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Adalimumab is an IgG1 antibody that actively crosses the placenta during pregnancy, with the highest transfer occurring during the third trimester. Infants born to mothers who received adalimumab during pregnancy may be at increased risk for infection for up to 5 months after the mother’s last injection. Administration of live vaccines to infants exposed to adalimumab in utero should be avoided for at least 5 months following the mother’s last adalimumab injection during pregnancy.

Data from the Humira Pregnancy Registry and published literature do not suggest an increased rate of major birth defects compared with the general population. However, higher rates of spontaneous abortion and preterm birth have been observed in some registry data for pregnant women exposed to adalimumab, although these outcomes may also be influenced by the underlying autoimmune disease itself. Women of childbearing potential should use effective contraception during treatment and for at least 5 months after the last dose.

Adalimumab has been detected in breast milk at very low concentrations (0.1–1% of maternal serum levels). Because monoclonal antibodies are large proteins, they are likely degraded in the infant’s gastrointestinal tract and systemic absorption is expected to be minimal. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for adalimumab and any potential adverse effects on the breastfed infant.

Vaccinations

Live vaccines should not be given concurrently with Ahzantive. There is insufficient data on the risk of secondary transmission of infection by live vaccines in patients receiving adalimumab. It is recommended that all patients, particularly pediatric patients, be brought up-to-date with all immunizations before initiating adalimumab therapy. Inactivated vaccines can generally be administered during adalimumab treatment, but the immune response may be diminished. Annual influenza vaccination with the inactivated vaccine is recommended for patients receiving adalimumab.

Driving and Operating Machinery

Ahzantive may have a minor influence on the ability to drive and use machines. Symptoms such as dizziness and visual disturbance have been reported following adalimumab administration. If affected, patients should not drive or operate machinery until symptoms resolve.

How Does Ahzantive Interact with Other Drugs?

Understanding the drug interaction profile of Ahzantive is essential for safe and effective therapy. As a monoclonal antibody, adalimumab is degraded through general protein catabolic pathways rather than through hepatic cytochrome P450 (CYP) enzyme metabolism. Therefore, traditional pharmacokinetic drug-drug interactions with small-molecule medications are not expected. However, there are important pharmacodynamic interactions and clinical considerations that must be taken into account.

The most critical drug interaction concern with adalimumab involves other immunosuppressive biologic agents. Combining adalimumab with other biologic DMARDs that also suppress the immune system significantly increases the risk of serious infections without providing additional clinical benefit. The following combinations should be avoided:

Methotrexate (MTX) deserves special mention as it is frequently co-administered with adalimumab, particularly in rheumatoid arthritis. Concomitant methotrexate reduces the formation of anti-drug antibodies (immunogenicity) against adalimumab and can reduce adalimumab clearance by approximately 29–44%. This results in higher serum trough levels of adalimumab, which may contribute to improved clinical outcomes. The combination of adalimumab plus methotrexate has been shown in landmark trials (such as PREMIER and OPTIMA) to be superior to either agent alone in achieving disease remission and preventing radiographic joint damage in RA.

Non-biologic DMARDs other than methotrexate — including sulfasalazine, hydroxychloroquine, and leflunomide — can also be safely used with adalimumab. No clinically significant pharmacokinetic interactions have been identified between adalimumab and these agents. Similarly, analgesics (paracetamol, opioids), non-steroidal anti-inflammatory drugs (NSAIDs such as ibuprofen, naproxen, diclofenac), and low-dose corticosteroids are routinely used alongside adalimumab without concerns for drug interactions.

What Is the Correct Dosage of Ahzantive?

Ahzantive should always be used exactly as prescribed by your healthcare provider. The medication is administered as a subcutaneous injection (under the skin) and is available as a solution for injection at a concentration of 40 mg/mL. Your doctor will determine the most appropriate dosing regimen based on your specific condition, disease severity, body weight (for certain indications), and response to treatment.

Adults

The recommended dosing varies by indication. The following table summarizes the standard adult dosing regimens:

The injection is given subcutaneously (under the skin) into the abdomen or front of the thigh. When self-injecting, rotate injection sites and avoid areas where the skin is tender, bruised, red, or hard. Each injection site should be at least 3 cm (approximately 1 inch) away from the previous site. If you miss a dose, inject the missed dose as soon as you remember and then continue with your regular schedule.

Children and Adolescents

For pediatric patients with juvenile idiopathic arthritis (JIA), dosing is weight-based. Children weighing 15 kg to less than 30 kg typically receive 20 mg every other week, while those weighing 30 kg or more receive 40 mg every other week. For pediatric Crohn’s disease (ages 6 and older), induction and maintenance doses are also weight-based. Your child’s physician will determine the exact dosing regimen. Ahzantive should be administered under the supervision of a healthcare provider experienced in treating pediatric autoimmune conditions.

Elderly Patients

No dose adjustment is required in elderly patients. However, the frequency of serious infections is higher in the elderly population in general. Elderly patients should be monitored more carefully for signs and symptoms of infection during and after treatment with Ahzantive. Extra vigilance is warranted given the age-related decline in immune function.

Missed Dose

If you miss a scheduled dose of Ahzantive, administer the injection as soon as you remember. Then resume your regular dosing schedule based on the date of the missed dose injection. Do not inject two doses at the same time to make up for a missed dose. Setting a reminder on your phone or calendar can help you maintain your dosing schedule consistently. If you are unsure about when to administer your next dose, contact your healthcare provider or pharmacist for guidance.

Overdose

In the event of an overdose, the patient should be monitored for signs of adverse reactions, and appropriate symptomatic treatment should be initiated. No specific antidote exists for adalimumab. In clinical trials, no dose-limiting toxicities were observed. The maximum tolerated dose has not been formally established. Given the approximately 14-day half-life of adalimumab, monitoring after overdose should continue for an appropriate period. If you suspect an overdose, contact your healthcare provider, local poison control center, or emergency services immediately.

What Are the Side Effects of Ahzantive?

Like all medicines, Ahzantive can cause side effects, although not everyone experiences them. As a TNF-alpha inhibitor, adalimumab modifies the immune system, which means that side effects related to infection susceptibility and immune-mediated reactions are particularly important to understand. The side effects are classified below by frequency based on data from clinical trials and post-marketing experience.

Anti-drug antibodies (ADAs) can develop during adalimumab therapy. The formation of ADAs may reduce drug efficacy and increase the risk of injection site reactions and hypersensitivity events. The incidence of ADAs is lower in patients receiving concomitant methotrexate or other immunosuppressive agents. If you notice that your medication is becoming less effective over time (loss of response), inform your doctor, as this may be related to ADA formation and require an adjustment in dosing or a switch to an alternative therapy.

If you experience any symptoms suggestive of a serious infection (persistent fever, weight loss, night sweats, cough, shortness of breath, blood in stools, or pain and warmth in a joint), new or worsening neurological symptoms (numbness, tingling, vision changes, weakness), signs of heart failure (increasing shortness of breath, ankle swelling), or any unusual symptoms, contact your healthcare provider immediately. Early detection and management of serious side effects is critical for ensuring safe treatment.

How Should You Store Ahzantive?

Proper storage of Ahzantive is essential to maintain its safety and effectiveness. As a biological product containing a protein (monoclonal antibody), adalimumab is sensitive to temperature extremes, light exposure, and physical agitation. Improper storage can lead to protein degradation, aggregation, or denaturation, which may reduce the drug’s effectiveness or increase the risk of adverse reactions.

The recommended storage conditions for Ahzantive are as follows:

• Temperature: Store refrigerated at 2–8 °C (36–46 °F). Do not freeze. If the product has been accidentally frozen, do not use it — discard it properly. Do not store near the freezer compartment of a refrigerator.
• Light protection: Keep Ahzantive in the original carton until ready for use to protect from light. Prolonged exposure to light can degrade the protein in the formulation.
• Room temperature storage: If necessary, a single pen or pre-filled syringe may be stored at room temperature (up to 25 °C / 77 °F) for a maximum of 14 days. Record the date of removal from the refrigerator on the carton. Once stored at room temperature, do not return the product to the refrigerator. Discard the product if not used within 14 days of removal from refrigeration.
• Handling: Do not shake the product vigorously. Excessive agitation can cause the protein to aggregate and form particles. Gently swirl the solution if needed.
• Inspection: Before each injection, visually inspect the solution. It should be clear and colorless to slightly yellow. Do not use if the solution is cloudy, discolored, or contains visible particles.

Keep Ahzantive out of the sight and reach of children. Do not use the medication after the expiration date printed on the carton and the label of the pen or syringe. The expiration date refers to the last day of that month. Do not dispose of unused medicines via household waste or wastewater. Ask your pharmacist about proper disposal methods. These measures help protect the environment.

What Does Ahzantive Contain?

Each Ahzantive injection contains the following:

• Active ingredient: Adalimumab 40 mg/mL. Adalimumab is a recombinant human IgG1 monoclonal antibody specific for human tumor necrosis factor alpha (TNF-alpha). It is produced by recombinant DNA technology in Chinese hamster ovary (CHO) cells and purified through a process that includes specific viral inactivation and removal steps.
• Inactive ingredients (excipients):
  • Sodium chloride — used to adjust the tonicity (salt concentration) of the solution to make it compatible with body fluids
  • Dibasic sodium phosphate dihydrate — a buffering agent that helps maintain the pH of the solution
  • Monobasic sodium phosphate dihydrate — a buffering agent working in conjunction with dibasic sodium phosphate
  • Sodium citrate — provides additional buffering capacity and contributes to protein stability
  • Citric acid monohydrate — works with sodium citrate to maintain the solution’s pH within the optimal range
  • Mannitol — a sugar alcohol used as a stabilizer to protect the protein from degradation
  • Polysorbate 80 — a surfactant that prevents protein aggregation and adsorption to container surfaces
  • Water for injection — the solvent for all dissolved components

The solution does not contain preservatives. Each pen or syringe is intended for single use only. Any unused portion should be discarded. The pH of the solution is approximately 5.8. Ahzantive contains sodium — less than 1 mmol (23 mg) per dose, which means it is essentially sodium-free. This is relevant for patients on a controlled sodium diet.

Ahzantive is supplied as a sterile, preservative-free solution for subcutaneous injection. The product is available in pre-filled syringes and may also be available in pre-filled pen format depending on market availability. Each unit contains 40 mg of adalimumab per mL. Consult your pharmacist or healthcare provider for information about the specific presentations available in your region.